Updated on 8 May 2025
Innovation ecosystem for biomedical engineering
Vice-Dean for Infrastructure and Organization, Head of Department at Silesian University of Technology
Zabrze, Poland
About
The health care sector in Poland and its innovation ecosystem is in the phase of intensive development. Growing opportunities in both the public and private sectors and new technologies requires establishing innovation ecosystem for the sector including: cooperation platform, technology transfer, entrepreneurship support. We have some experience in this area but still looking for new opportunities, especially with partners abroad.
Similar opportunities
Expertise
R&D support in the field of biomedical engineering
Agnieszka Droździok
Chief administration specialist at European HealthTech Innovation Center, Silesian University of Technology
Zabrze, Poland
Project cooperation
Horizon Europe: Digital pharma marketplace for licensing & distribution
Mariusz Wituszynski
Investor Relations at Nubinno Connect
Warsaw, Poland
Project cooperation
- Partner seeks Consortium/Coordinator
- Consortium/Coordinator seeks Partners
- HORIZON-HLTH-2025-01-TOOL-02: Advancing cell secretome-based therapies
- Cluster Food (CL6): HORIZON-CL6-2025-02-FARM2FORK-12 Nutrition and Mental Health
- HORIZON-CL4-2025-03-HUMAN-18: GenAI4EU central Hub (CSA) (AI/Data/Robotics Partnership)
- HORIZON-HLTH-2025-03-TOOL-01-two-stage: Enhancing cell therapies with genomic techniques
- HORIZON-HLTH-2025-01-IND-01: Optimising the manufacturing of Advanced Therapy Medicinal Products (ATMPs)
- HORIZON-CL4-2025-04-DATA-03: Software Engineering for AI and generative AI (RIA) (AI/Data/Robotics Partnership)
- HORIZON-CL4-2025-04-DIGITAL-EMERGING-06: Challenge-Driven GenAI4EU Booster (RIA) (AI/Data/Robotics Partnership)
- HORIZON-CL4-2025-03-DATA-13: Fostering Innovative and Compliant Data Ecosystems (IA) (AI, Data and Robotics Partnership)
- Cluster Health (CL1): HORIZON-HLTH-2025-01-DISEASE-04: Leveraging artificial intelligence for pandemic preparedness and response
- HORIZON-CL4-2025-04-DATA-02: Empowering AI/generative AI along the Cognitive Computing continuum (RIA) (AI/Data/Robotics Partnership)
- HORIZON-HLTH-2025-01-IND-02: Digitalisation of conformity assessment procedures of medical devices and in vitro diagnostic medical devices
- Cluster Health (CL1): HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage: Advancing knowledge on the impacts of micro- and nanoplastics on human health
- Cluster Health (CL1): HORIZON-HLTH-2025-01-CARE-01: End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU)
- Cluster Health (CL1): HORIZON-HLTH-2025-03-ENVHLTH-01-two-stage: The impact of pollution on the development and progression of brain diseases and disorders
- Cluster Health (CL1): HORIZON-HLTH-2025-03-DISEASE-02-two-stage: Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders
- Cluster Health (CL1): HORIZON-HLTH-2025-03-STAYHLTH-01-two-stage: Improving the quality of life of persons with intellectual disabilities and their families
- HORIZON-HLTH-2025-01-IND-03: Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative (“breakthrough”) devices
- Cancer Mission: HORIZON-MISS-2025-02-CANCER-02: Understanding the effects of environmental exposure on the risk of paediatric, adolescent and young adult cancers
- HORIZON-HLTH-2025-01-DISEASE-03: Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential
- HORIZON-HLTH-2025-01-DISEASE-01: Randomised controlled trials to test safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections
- Cluster Health (CL1): HORIZON-HLTH-2025-01-TOOL-03: Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU)
- HORIZON-HLTH-2025-03-DISEASE-06-two-stage: Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD)
Robert Lugowski
CEO at CliniNote
Warsaw, Poland